Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 25/2/2021
SIETES contiene 93212 citas

 
 
 1 a 20 de 691 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Hetland ML, Haavardsholm EA, Rudin A, Nordtröm D, Nurmohamed M, Gudbjornsson B, Lampa J, et al.. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial. BMJ 2020;371:2 de diciembre. [Ref.ID 103805]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Chappel JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott AB, Flach B, Lin BC, Doria-Rose NA, O'Dell S, Schmidt SD, Neuzil KM, Bennett H, Leav B, Makowski M, Albert J, Cross K, Edara V-V, Floyd K, Suthar MS, Buchanan W, Luke CJ, Ledgerwood JE, Mascola JR, Graham BS, Beigel JH, for the mRNA-1273 Study Group. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med 2020:3 de diciembre. [Ref.ID 103800]
3.Enlace a cita original Cita con resumen
Anónimo. Coronavirus (COVID-19) Update: FDA authorizes monoclonal antibodies for treatment of COVID-19. U.S. Food and Drug Administration 2020:21 de noviembre. [Ref.ID 103785]
4.Enlace a cita originalTiene citas relacionadas Cita con resumen
Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P, on behalf of the PLACID Trial Collaborators. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ 2020;371:22 de octubre. [Ref.ID 103770]
5. Cita con resumen
Anónimo. Three new drugs for the prevention of migraine. Drug Ther Bull 2020;58:octubre. [Ref.ID 103746]
6. Cita con resumen
Parsons L. Regeneron seeks US emergency use authorisation for COVID-19 antibody cocktail. PMLiVE 2020:12 de octubre. [Ref.ID 103741]
7.Enlace a cita originalTiene citas relacionadas Cita con resumen
Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott AB, Flach B, et al for the mRNA-1273 Study Group. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020;383:17 de diciembre. [Ref.ID 103729]
8. Cita con resumen
Parsons L. Roche’s Actemra fails in late-stage severe COVID-19 study. PMLiVE 2020:29 de julio. [Ref.ID 103699]
9.Enlace a cita original Cita con resumen
Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L, Zhou N, Petty LA, Baang JH, Dillman NO, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis 2020:11 de julio. [Ref.ID 103688]
10. Cita con resumen
Kunchok A, Aksamit Jr AJ, Davis III JM, Kantarci OH, Keegan M, Pittock SJ, Weinshenker BG, McKeon A. Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events. JAMA Neurology 2020;77:agosto. [Ref.ID 103656]
14. Cita con resumen
Geldhof A, Slater J, Clark M, Chandran U, Coppola D. Exposure to infliximab during pregnancy: post-marketing experience. Drug Saf 2020;43:febrero. [Ref.ID 103539]
15. Cita con resumen
Taylor P. BMS completes Celgene merger after FTC okay. PMLiVE 2019:18 de noviembre. [Ref.ID 103210]
16.Enlace a cita original Cita con resumen
Anónimo. Towards better patient care: drugs to avoid in 2019. Prescrire Int 2019;39:abril. [Ref.ID 103075]
17. Cita con resumen
Silverman E. STAT Plus: AbbVie is sued for using Humira patent deals to block competition in the U.S.. STAT Daily Recap 2019:20 de marzo. [Ref.ID 103062]
18. Cita con resumen
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby J-F, Tricoci P, White HD, Zeiher AM, for the ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018;379:29 de noviembre. [Ref.ID 102917]
19.Enlace a cita original Cita con resumen
Xu C, Chen Y-P, Du X-J, Liu J-Q, Huang C-L, Chen L, Zhou G-Q, Li W-F, Mao Y-P, Hsu C, Liu Q, Lin A-H, Tang L-L, Sun Y, Ma J. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ 2018;363:8 de noviembre. [Ref.ID 102847]
20.Enlace a cita original Cita con resumen
Sinha MS, Curfman GD, Carrier MA. Antitrust, market exclusivity, and transparency in the pharmaceutical industry. JAMA 2018;319:12 de junio. [Ref.ID 102779]
Seleccionar todas
 
 1 a 20 de 691 siguiente >>